Fecha de publicación: 11/03/1997 Fuente: WIPO "royal jelly" PROBLEM TO BE SOLVED: To obtain an angiotensin-converting enzyme inhibitor and an insulin- like acting agent which contain a component included in royal jelly and are useful in prevention and therapy of hypertension and diabetes safety without side effect. SOLUTION: These preparatioins contain trans-10-hydroxy-decenoic acid (addreviated as HDA) as an active ingredient. HDA has inhibitory action on an angiotensin-converting enzyme and an inhibitory action on lipolysis in fat cells to promote fat synthesis like insulin. HDA is mixed with a carrier, an excipient, diluent and the like appropriatelhy to prepare tablets, capsules, grains, injection solution, suppository and the like. When it is used as an angiotensin- converting enzyme inhibitor, the daily dose is 100-200mg/man (60kg body weight) twice a day while the dose is 100-200mg/man (60kg body weight) about three times a day, when it is used as an insulin-like acting agent.COPYRIGHT: (C)1997,JPO